Han Kun represents Shanghai Healthcare Capital in leading an investment in Guangmai Medical
July, 2024 - Beijing, Mainland China
Han Kun Law Offices recently represented Shanghai Healthcare Capital in the successful completion of a financing of several hundred million yuan for Shanghai Guangmai Medical Technology Co., Ltd. ("Guangmai Medical"). Guangmai Medical is committed to organic innovation and research and development of digital molecular imaging equipment. With its profound accumulation and continuous iteration in the field of semiconductor detection technology, it has long been leading the forefront of global molecular imaging technology innovation. In 2007, Guangmai Medical created the world's first digital heart-specific single-photon emission and computed tomography imaging system (SPECT system) D-SPECT®, which currently holds more than half of the global market share in heart-specific SPECT equipment.
Authorized by the Shanghai municipal government and founded by Shanghai Industrial Investment (Holdings) Co., Ltd (SIIC), Shanghai Healthcare Capital was established with total targeted assets under management of 50 billion RMB. Shanghai Healthcare Capital focuses on breakthrough biologics, innovative chemical drugs, high-end medical devices and diagnostics, and innovative business platforms, not only through the integration of capital and industrial resources but also international and domestic operations.
